Hasan Cagri Yildirim
Overview
Explore the profile of Hasan Cagri Yildirim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Akyildiz A, Ismayilov R, Guven D, Yildirim H, Tatar O, Kus F, et al.
Vascular
. 2024 Mar;
:17085381241241853.
PMID: 38523367
Aim: Sirolimus, a mammalian target of rapamycin inhibitor, inhibits cell growth and proliferation by controlling ribosome biogenesis and protein synthesis in vascular anomalies and cancers. However, most sirolimus studies on...
12.
Yildirim H, Kapar C, Koksal B, Seyyar M, Sanci P, Guliyev M, et al.
J Chemother
. 2024 Mar;
37(1):69-75.
PMID: 38497444
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the...
13.
Guner G, Ozcakar L, Baytar Y, Onur M, Demir M, Aktas B, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473418
The objective of this study was to explore the possible association between low skeletal muscle mass (SMM)-assessed by computed tomography (CT) and ultrasound (US)-and hematologic toxicity in cancer patients. A...
14.
Yildirim H, Anik H, Ozdemir D, Ismayilov R, Akyildiz A, Cayiroz K, et al.
Biomol Biomed
. 2024 Mar;
24(4):998-1003.
PMID: 38447002
This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor...
15.
Yildirim H, Kutlu Y, Mutlu E, Aykan M, Korkmaz M, Yalcin S, et al.
Int J Clin Oncol
. 2024 Feb;
29(3):258-265.
PMID: 38310597
Introduction: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of...
16.
Yildirim H, Kus F, Guven D, Karaca E, Kaygusuz Y, Dizdar O, et al.
J Immunother Precis Oncol
. 2023 Dec;
6(4):170-176.
PMID: 38143956
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers...
17.
Kertmen N, Kavgaci G, Yildirim H, Dizdar O
Anticancer Drugs
. 2023 Nov;
35(3):302-304.
PMID: 38018812
Tyrosine kinase inhibitors (TKIs) have transformed cancer treatment but are associated with cardiovascular toxicity, including heart failure. This review examines the cardiotoxicity of pazopanib, a VEGFR-TKI, through two case reports...
18.
Avci O, Iriagac Y, Cavdar E, Karaboyun K, Araz M, Sakalar T, et al.
J Geriatr Oncol
. 2023 Sep;
14(8):101604.
PMID: 37683369
Introduction: In this study, the toxicities and management of palbociclib and ribociclib in older patients (≥65 years) with metastatic breast cancer patients were investigated. Materials And Methods: Among older patients...
19.
Yildirim H, Kavgaci G, Chalabiyev E, Dizdar O
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568696
Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease. Early diagnosis is crucial and can significantly...
20.
Guven D, Yildirim H, Kus F, Erul E, Kertmen N, Dizdar O, et al.
Expert Rev Anticancer Ther
. 2023 May;
23(10):1049-1059.
PMID: 37224429
Introduction: The therapeutic armamentarium for the neoadjuvant treatment of triple-negative breast cancer (TNBC) has significantly expanded with the hopes of improving pathological complete response (pCR) rates and the possibility of...